1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 64 (Search time: 0.006 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2002High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBranford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.; Hughes, T.
2006Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaDruker, B.; Guilhot, F.; O'Brien, S.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.; Silver, R.; Goldman, J.; Stone, R.; Cervantes, F.; Hochhaus, A.; Powell, B.; Gabrilove, J.; Rousselot, P.; Reiffers, J.; Cornelissen, J.; Hughes, T.; Agis, H.; Fischer, T.; et al.
2017Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemiaSopper, S.; Mustjoki, S.; White, D.; Hughes, T.; Valent, P.; Burchert, A.; Gjertsen, B.; Gastl, G.; Baldauf, M.; Trajanoski, Z.; Giles, F.; Hochhaus, A.; Ernst, T.; Schenk, T.; Janssen, J.; Ossenkoppele, G.; Porkka, K.; Wolf, D.
2000Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual triad in a patient 6 months post mini-allogeneic peripheral stem cell transplant for chronic myeloid leukemiaSzabo, F.; Horvath, N.; Seimon, S.; Hughes, T.
2014Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibHughes, T.; Saglio, G.; Kantarjian, H.; Guilhot, F.; Niederwieser, D.; Rosti, G.; Nakaseko, C.; De Souza, C.; Kalaycio, M.; Meier, S.; Fan, X.; Menssen, H.; Larson, R.; Hochhaus, A.
2014Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBranford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
2014Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombinationParker, W.; Phillis, S.; Yeung, D.; Hughes, T.; Scott, H.; Branford, S.
2016TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyNievergall, E.; Reynolds, J.; Kok, C.; Watkins, D.; Biondo, M.; Busfield, S.; Vairo, G.; Fuller, K.; Erber, W.; Sadras, T.; Grose, R.; Yeung, D.; Lopez, A.; Hiwase, D.; Hughes, T.; White, D.
2016Chronic myeloid leukemia: reminiscences and dreamsMughal, T.; Radich, J.; Deininger, M.; Apperley, J.; Hughes, T.; Harrison, C.; Gambacorti-Passerini, C.; Saglio, G.; Cortes, J.; Daley, G.
2013Which TKI? An embarrassment of riches for chronic myeloid leukemia patientsHughes, T.; White, D.

Discover